<div id="readability-page-1">LivaNova ( (LIVN) ) has issued an update.LivaNova PLC held its 2026 Annual General Meeting of Shareholders on June 10, 2026, where investors approved the election of eleven directors for terms expiring at the 2027 AGM and endorsed the company’s U.S. and UK executive compensation reports. Shareholders also ratified the appointments of PricewaterhouseCoopers LLP as both the U.S. independent registered public accounting firm and the UK statutory auditor for 2026, and authorized the board to set the auditor’s remuneration.The AGM further strengthened the board’s financial and capital management flexibility by authorizing directors to allot new shares, disapply existing shareholders’ pre-emption rights up to a defined nominal amount, and approve share repurchase contracts covering up to 10% of issued ordinary shares. Investors adopted the company’s audited UK statutory accounts for 2025, signaling broad shareholder support for LivaNova’s governance framework and capital allocation strategy, with implications for future equity issuance and buyback activity. The most recent analyst rating on (LIVN) stock is a Hold with a $76.00 price target. To see the full list of analyst forecasts on LivaNova stock, see the LIVN Stock Forecast page. <div> Spark’s Take on LIVN Stock According to Spark, TipRanks’ AI Analyst, LIVN is a Outperform. The score is driven mainly by improving fundamentals (profitability, lower leverage, solid cash generation) and strong technical uptrend signals. This is reinforced by a positive earnings call with raised 2026 guidance and multiple operational/regulatory tailwinds. The main offset is valuation (P/E ~39) alongside ongoing cash flow variability and some execution risks (supply constraints and reimbursement uncertainty). To see Spark’s full report on LIVN stock, click here. </div><div> More about LivaNova LivaNova PLC is a medical technology company focused on developing and commercializing devices and therapies, particularly in areas such as cardiovascular and neuromodulation care. The company operates globally, serving hospitals and healthcare providers with advanced medical solutions aimed at improving patient outcomes and addressing complex clinical needs. Average Trading Volume: 800,493 Technical Sentiment Signal: Buy Current Market Cap: $4.31B </div><div> For a thorough assessment of LIVN stock, go to TipRanks’ Stock Analysis page. </div></div>

LIVN

LivaNova shareholders approved key proposals at the 2026 AGM, including director elections, executive compensation reports, and auditor appointments. The board received authorization for share allotments, pre-emption rights disapplication, and buybacks up to 10% of shares. Analysts maintain a 'Hold' rating with a $76 target, while TipRanks' AI suggests 'Outperform' based on improved fundamentals and raised guidance.

LivaNova Shareholders Back 2026 AGM Proposals and Governance